Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

Grant A. McArthur(The University of Melbourne), Axel Hauschild(University Hospital Schleswig-Holstein), John M. Kirkwood(UPMC Hillman Cancer Center), John B.A.G. Haanen(Leiden University Medical Center), Michele Maio(University of Siena), Alessandro Testori(European Organisation for Research and Treatment of Cancer), Keith T. Flaherty(Cancer Research Center), Célèste Lebbé(Inserm), Omid Hamid(Cedars-Sinai Medical Center), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Dirk Schadendorf(National Center for Tumor Diseases), Kerstin Trunzer(Roche (Switzerland)), Thomas Jouary(Hôpital Saint-André), Alexander M.M. Eggermont(University Medical Center Utrecht), David Hogg(University of Leeds), Paul Lorigan(Manchester Academic Health Science Centre), Ivor Caro(Genentech), Jeffrey A. Sosman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), James Larkin(Trinity College Dublin), Ming Yin(Genentech), Antoni Ribas(University of California, Los Angeles), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Reinhard Dummer(University Hospital of Zurich), Caroline Robert(Institut Gustave Roussy), S. O'Day(Beverly Hills Cancer Center), Claus Garbe(University of Tübingen), Suzanne Cheng(Roche (Switzerland)), Brigitte Dréno(Nantes Université)

The Lancet Oncology

February 6, 2014

Cited by 978

|New England Journal of Medicine|2012|12.6k

|New England Journal of Medicine|2012|8k

|New England Journal of Medicine|2011|7.7k

|New England Journal of Medicine|2015|5.8k

|New England Journal of Medicine|2014|5.3k

Related Papers